Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Immvira Biopharmaceuticals Co. Limited has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is under review by 1 distinct examiner in 1 distinct art unit. The current prosecution footprint is highly specific to the application, reflecting a focused technical engagement in the biopharmaceutical sector. This allows for a concentrated effort on the specific claims of the pending matter.
KINSEY WHITE, NICOLE ERIN is the busiest examiner for this portfolio, managing 1 pending office action. With only 1 distinct examiner and 1 distinct art unit, the prosecution strategy is focused on a single point of contact. This concentration is typical for portfolios with a single active matter in the Biotechnology & Pharmaceuticals sector. Practitioners should analyze the examiner's history to tailor their arguments effectively for this specific application.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KINSEY WHITE, NICOLE ERIN | 1 | 58.1% | +16.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18286103 | GENETICALLY MODIFIED ONCOLYTIC HERPES SIMPLEX VIRUS DELIVERING CHEMOKINE AND TUMOR ASSOCIATED/SPECIFIC ANTIGEN | KINSEY WHITE, NICOLE ERIN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18286103 | GENETICALLY MODIFIED ONCOLYTIC HERPES SIMPLEX VIRUS DELIVERING CHEMOKINE AND TUMOR ASSOCIATED/SPECIFIC ANTIGEN | KINSEY WHITE, NICOLE ERIN | — |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18286103 | GENETICALLY MODIFIED ONCOLYTIC HERPES SIMPLEX VIRUS DELIVERING CHEMOKINE AND TUMOR ASSOCIATED/SPECIFIC ANTIGEN | KINSEY WHITE, NICOLE ERIN | 1672 | §103§112 | Non-Final OA | — | Pending | Oct 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialImmvira Biopharmaceuticals Co. Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Nicole Erin Kinsey White has the most, with 1 of Immvira Biopharmaceuticals Co. Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
